載入...
Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic)...
Na minha lista:
| 發表在: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
SAGE Publications
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6024342/ https://ncbi.nlm.nih.gov/pubmed/29977351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918778483 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|